Navigation Links
Uptake Medical Announces TGA Approval of InterVapor for Patients With Severe Emphysema
Date:12/21/2011

TUSTIN, Calif., Dec. 21, 2011 /PRNewswire/ -- Uptake Medical® today announced that it received Australian Therapeutic Goods Administration (TGA) approval for its InterVapor™ System for endoscopic lung volume reduction for the treatment of severe emphysema.  InterVapor is the first non-surgical, endoscopic lung volume reduction system for the treatment of severe emphysema that uses the body's natural healing processes without leaving implants or foreign materials in the lung.

Clinical efficacy of InterVapor has been established by the multi-center VAPOR trial which showed a reduction in lung volume as well as statistical and clinical significance in lung function improvement (FEV1) and health-related quality of life (SGRQ) at six months. 

"Our involvement with Uptake Medical and InterVapor goes back to the first usage in patients, and we are delighted to see the TGA approval," commented Professor Gregory Snell, head of lung transplant services at the Alfred Hospital in Melbourne, Australia.  "InterVapor has continued to demonstrate clinical efficacy and safety and we look forward to offering InterVapor to our patients."

VAPOR trial investigator, Dr. Peter Hopkins of Prince Charles Hospital in Brisbane, provided insights into the relevance of new treatment options for emphysema.  "Emphysema is a debilitating condition and this patient population is in need of new treatment options.  The ability to offer InterVapor to our patients represents an important step in furthering the standard of care for the treatment of severe emphysema."

"Capping the year by obtaining TGA approval in Australia is another important milestone for Uptake Medical," said R. King Nelson, President and Chief Executive Officer, Uptake Medical. "We look forward to working with our distributor partner, Aurora BioScience, as we introduce InterVapor in Australia 2012."

About Emphysema/COPD

The global incidence of Chronic Obstructive Pulmonary Disease (COPD), which includes emphysema, is on the rise and will become the third leading cause of death by 2030. In the U.S., where nearly 5 million people are diagnosed with emphysema, it already holds this position with one person dying every 4 minutes from COPD. Debilitating and costly, nearly $50 billion was spent addressing the direct and indirect costs associated with COPD in the U.S. in 2010.

About Uptake Medical

Uptake Medical is focused on the development and commercialization of innovative, non-surgical treatments for lung diseases.  InterVapor™ is the first and only approach to endoscopic lung volume reduction for people with severe emphysema that uses the body's natural healing process without leaving any implants or foreign materials in the lung. In clinical studies, InterVapor has demonstrated clinically meaningful improvements in breathing function, exercise capacity and quality of life. Headquartered in Tustin, Calif., Uptake Medical® received the CE mark and TGA approval to commercialize InterVapor. More information can be found at www.uptakemedical.com.

About Aurora BioScience Pty Ltd

Headquartered in Sydney Australia, Aurora BioScience is committed to providing advanced, high quality medical devices and healthcare products to assist medical professionals within Australia, New Zealand and the Asia Pacific healthcare markets contribute to the enhancement of their patients' quality of life. Our areas of interest include pulmonology, cancer therapies, neurology, haematology and blood products. For more information, please visit www.aurorabioscience.com.au.

Uptake Medical and InterVapor are registered trademarks and trademarks of Uptake Medical.


'/>"/>
SOURCE Uptake Medical
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. The Continued Uptake of Key Agents Such as Januvia, Bydureon and Byetta Will Drive The Type 2 Diabetes Drug Market to Nearly Double From $19 Billion in 2009 to $36 Billion in 2019
2. Introduction of New Products and Increased Uptake of Innovative Materials to Drive US Bone Graft Substitute Market to Nearly $2.3 Billion by 2015
3. Driven by the Uptake of Several Emerging Agents, the MRSA Drug Market Will Increase From $631 Million in 2009 to $752 Million in 2019
4. Uptake Medical Names J.C. MacRae as Chief Financial Officer
5. The Harley Medical Group Sees an Uptake in Surgery Bookings for Christmas
6. Uptake Medical Announces Scott Huennekens Elected to Board of Directors
7. Reportlinker Adds Pharmaceutical Key Trends 2011 - Generics Market Overview: Patent cliff set to drive global generic uptake despite tougher market conditions
8. Reportlinker Adds Opioids Market to 2017 - Steady Uptake of Oxycontin and High Incidence Of Diseases Such As Cancer And Arthritis to Drive the Market
9. Uptake Medical® Expands Executive Team, Announces European General Manager Lloyd Mencinger
10. Uptake Medical Receives CE Mark for InterVapor - Endoscopic Lung Volume Reduction for Treatment of Severe Emphysema - and Announces Positive Clinical Results
11. Womens Health Therapeutics, Analysis and Market Forecasts to 2016 - High Unmet Need will Drive the Uptake of Novel Drugs in the Menopause and Osteoporosis Markets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... Dec. 7, 2016  Ionis Pharmaceuticals, Inc. (NASDAQ: IONS ... present a company overview at the BMO Capital Markets Prescriptions for ... York, NY . A live webcast of the ... the Ionis website.  The replay will be available within 48 hours ... ...
(Date:12/7/2016)... 7, 2016 Today, Stock-Callers.com presents four ... JAZZ ), Anthera Pharmaceuticals Inc. (NASDAQ: ANTH ... AveXis Inc. (NASDAQ: AVXS ). From its peak ... 37% to reach a level equal to what it saw ... approximately 14% for the year, it has still out-performed other ...
(Date:12/7/2016)... According to the latest market ... Study on Multiplex Detection Immunoassay: North America to Dominate ... detection immunoassay market is expected to witness a CAGR of ... ...      (Logo: http://photos.prnewswire.com/prnh/20161114/438683LOGO) ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... ... They are musicians and librarians, fashion designers and fitness instructors, actors, athletes and ... around the nation. What do they have in common? All have been affected by ... new photographic exhibit debuting Friday, December 9 at Logan International Airport in Boston. , ...
(Date:12/7/2016)... ... December 07, 2016 , ... When it came time to blow out his candles on ... later, the Pediatric Heart Transplant team at Joe DiMaggio Children’s Hospital surprised his ... the hospital’s 30th heart transplant recipient. , “He was playing at home, when we ...
(Date:12/7/2016)... , ... December 07, 2016 , ... ... connectors, is now promoting to the US market its advanced highly customizable contact ... and ODU TURNTAC®. These advanced technologies are ideal for a wide range ...
(Date:12/7/2016)... MI (PRWEB) , ... December 07, 2016 , ... ... and financial consultation services from offices located in South Lyon, Dewitt, Williamston, East ... benefit a basketball coach who needs treatment for a brain tumor. , Jason ...
(Date:12/7/2016)... Folsom, CA (PRWEB) , ... December 07, 2016 ... ... that provides insurance and financial consultation services to residents in the Sacramento/Folsom region, ... Choice Another Chance treatment facility. , The Another Choice Another Chance treatment center ...
Breaking Medicine News(10 mins):